{"id":"sodium-phenylacetate","_fda":{"id":"fd646c47-7fcd-4d60-8f6c-29e13f611c6d","set_id":"0f17c50f-3761-4470-bf3b-63837a287b8a","openfda":{"upc":["0370710192617"],"unii":["OJ245FE5EU","48N6U1781G"],"route":["INTRAVENOUS"],"rxcui":["2560228"],"spl_id":["fd646c47-7fcd-4d60-8f6c-29e13f611c6d"],"brand_name":["Sodium phenylacetate and Sodium benzoate"],"spl_set_id":["0f17c50f-3761-4470-bf3b-63837a287b8a"],"package_ndc":["70710-1926-1"],"product_ndc":["70710-1926"],"generic_name":["SODIUM PHENYLACETATE AND SODIUM BENZOATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["SODIUM BENZOATE","SODIUM PHENYLACETATE"],"manufacturer_name":["Zydus Pharmaceuticals USA Inc."],"application_number":["ANDA217526"],"is_original_packager":[true]},"version":"5","pregnancy":["8.1 Pregnancy Risk Summary Available data on the combination use of Sodium Phenylacetate and Sodium Benzoate in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with Sodium Phenylacetate and Sodium Benzoate Injection. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively."],"overdosage":["10 OVERDOSAGE Overdosage has been reported during Sodium Phenylacetate and Sodium Benzoate Injection treatment in urea cycle-deficient patients. All patients in the uncontrolled open-label study were to be treated with the same dose of Sodium Phenylacetate and Sodium Benzoate Injection. However, some patients received more than the dose level specified in the protocol. In 16 of the 64 deaths, the patient received a known overdose of Sodium Phenylacetate and Sodium Benzoate Injection. Causes of death in these patients included cardiorespiratory failure/arrest (6 patients), hyperammonemia (3 patients), increased intracranial pressure (2 patients), pneumonitis with septic shock and coagulopathy (1 patient), error in dialysis procedure (1 patient), respiratory failure (1 patient), intractable hypotension and probable sepsis (1 patient), and unknown (1 patient). Additionally, other signs of intoxication may include obtundation (in the absence of hyperammonemia), hyperventilation, a severe compensated metabolic acidosis, perhaps with a respiratory component, large anion gap, hypernatremia and hyperosmolarity, progressive encephalopathy, cardiovascular collapse, and death. In case of overdose of Sodium Phenylacetate and Sodium Benzoate Injection, discontinue the drug and institute appropriate emergency medical monitoring and procedures. In severe cases, the latter may include hemodialysis (procedure of choice) or peritoneal dialysis (when hemodialysis is unavailable)."],"description":["11 DESCRIPTION Sodium Phenylacetate and Sodium Benzoate Injection 10% per 10% (a nitrogen binding agent), is a sterile, concentrated, aqueous solution of sodium phenylacetate and sodium benzoate. The pH of the solution is between 7.0 and 8.0. Sodium phenylacetate is a white to off-white powder. It is soluble in water. Sodium benzoate is a white to off-white powder that is readily soluble in water. Figure 1 Sodium phenylacetate has a molecular weight of 158.14 and the molecular formula C 8 H 7 NaO 2 . Sodium benzoate has a molecular weight of 144.10 and the molecular formula C 7 H 5 NaO 2 . Each mL of Sodium Phenylacetate and Sodium Benzoate Injection contains 100 mg of sodium phenylacetate and 100 mg of sodium benzoate, and Water for Injection. Sodium hydroxide and/or hydrochloric acid may have been used for pH adjustment. Sodium Phenylacetate and Sodium Benzoate Injection is a sterile, concentrated solution intended for intravenous administration via a central venous catheter only after dilution [ see Dosage and Administration (2) ]. structure-figure-01"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Sodium Phenylacetate and Sodium Benzoate Injection 10% per 10% is clear and almost colorless solution supplied in a sterile, non-pyrogenic, single-dose glass vial. NDC 70710-1926-1 single-dose vial containing 20 mL of Sodium Phenylacetate and Sodium Benzoate Injection 10% per 10%. Storage: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)."],"geriatric_use":["8.5 Geriatric Use Clinical studies of Sodium Phenylacetate and Sodium Benzoate Injection did not include any patients aged 65 and over to determine whether they respond differently from younger patients. Urea cycle disorders are presently diseases of the pediatric and younger adult populations. No pharmacokinetic studies of Sodium Phenylacetate and Sodium Benzoate Injection have been performed in geriatric patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy in this patient population."],"pediatric_use":["8.4 Pediatric Use Sodium Phenylacetate and Sodium Benzoate Injection has been used as a treatment for acute hyperammonemia in pediatric patients including patients in the early neonatal period [ see Dosage and Administration (2) ]."],"effective_time":"20231030","nursing_mothers":["8.2 Lactation Risk Summary There are no data on the presence of sodium phenylacetate, sodium benzoate in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Sodium Phenylacetate and Sodium Benzoate Injection and any potential adverse effects on the breastfed infant from Sodium Phenylacetate and Sodium Benzoate Injection or from the underlying maternal condition."],"clinical_studies":["14 CLINICAL STUDIES The efficacy of Sodium Phenylacetate and Sodium Benzoate Injection in improving patient survival of acute hyperammonemic episodes was demonstrated in an analysis of 316 patients (1045 episodes of hospitalization) treated between 1981 and 2003. The demographic characteristics and diagnoses of the patient population are shown in Table 3. Table 3: Baseline Characteristics and Diagnoses of Study Population OTC = ornithine transcarbamylase deficiency ASS = argininosuccinate synthetase deficiency CPS = carbamyl phosphate synthetase deficiency ASL = argininosuccinate lyase deficiency ARG = arginase deficiency THN = transient hyperammonemia of the newborn * For the summary at the patient level, data obtained at first episode used. ** Diagnosis unknown or pending (33 episodes), acidemia (14 episodes), HHH syndrome (6 episodes), carnitine translocase deficiency (4 episodes), liver disease (3 episodes), HMG CoA lyase deficiency (1 episode), non-ketotic hyperglycinemia (1 episode), suspected fatty acid oxidation deficiency (1 episode), and valproic-acid-induced hyperammonemia (1 episode). Patients * N=316 Gender Male 158 (51%) Female 150 (49%) N 310 Age (years) Mean (SD) 6.2 (8.54) Min–Max 0.0–53.0 0–30 days 104 (34%) 31 days–2 years 55 (18%) Age groups > 2–12 years 90 (29%) > 12–16 years 30 (10%) > 16 years 31 (10%) OTC 146 (46%) ASS 71 (22%) CPS 38 (12%) Enzyme deficiency ASL 7 (2%) ARG 2 (< 1%) THN 2 (< 1%) Other ** 56 (18%) On admission to the hospital, patients with hyperammonemia and a suspected or confirmed urea cycle disorder (UCD) diagnosis were treated with a bolus dose of 0.25 g/kg (or 5.5 g/m 2 ) sodium phenylacetate + 0.25 g/kg (or 5.5 g/m 2 ) sodium benzoate over a period of 90 minutes to 6 hours, depending on the specific UCD. Infusions also contained arginine; the dose of arginine depended on the specific UCD. After completion of the bolus dose, maintenance infusions of the same dose over 24 hours were continued until the patient was no longer hyperammonemic or oral therapy could be tolerated. The mean (SD) duration of treatment was 4.6 (6.45) days per episode, and ranged from 1 to 72 days. Survival was substantially improved after Sodium Phenylacetate and Sodium Benzoate Injection treatment compared with historical values (estimated 14% 1-year survival rate with dietary therapy alone) and with dialysis (estimated 43% survival of acute hyperammonemia). Eighty percent of patients (252 of 316) survived their last episode. Of the 64 patients who died, 53 (83%) died during their first hyperammonemic episode. Of the 104 neonates (<30d) treated with Sodium Phenylacetate and Sodium Benzoate Injection, 34 (33%) died during the first hyperammonemic episode. Ammonia levels decreased from very high levels (>4 times the upper limit of normal [ULN]) to lower levels in 91% of episodes after treatment. In patients responding to therapy, mean ammonia concentrations decreased from 200.9 umol/L at hour zero to 101.6 umol/L within four hours of initiation of Sodium Phenylacetate and Sodium Benzoate Injection therapy and were maintained. Hemodialysis is recommended for those patients whose plasma ammonia levels fail to fall below 150 µmol/L or by more than 40% within 4 to 8 hours after receiving Sodium Phenylacetate and Sodium Benzoate Injection. A shift from high (≤4 times ULN) to very high (>4 times ULN) levels was observed in only 4% of the episodes. Overall, investigators rated neurological status as improved, much improved, or the same in 93% of episodes, and overall status in response to treatment as improved, much improved, or the same in 97% of episodes. Recovery from coma was observed in 97% of episodes where coma was present at admission (111 of 114 episodes)."],"pharmacodynamics":["12.2 Pharmacodynamics In patients with hyperammonemia due to deficiencies in enzymes of the urea cycle, Sodium Phenylacetate and Sodium Benzoate Injection has been shown to decrease elevated plasma ammonia levels. These effects are considered to be the result of reduction in nitrogen overload through glutamine and glycine scavenging by Sodium Phenylacetate and Sodium Benzoate Injection in combination with appropriate dietary and other supportive measures."],"pharmacokinetics":["12.3 Pharmacokinetics The pharmacokinetics of intravenously administered Sodium Phenylacetate and Sodium Benzoate Injection was characterized in healthy adult volunteers. Both benzoate and phenylacetate exhibited nonlinear kinetics. Following 90 minute intravenous infusion mean AUC last for benzoate was 20.3, 114.9, 564.6, 562.8, and 1599.1 mcg/mL following doses of 1, 2, 3.75, 4, and 5.5 g/m 2 , respectively. The total clearance decreased from 5.19 to 3.62 L/h/m 2 at the 3.75 and 5.5 g/m 2 doses, respectively. Similarly, phenylacetate exhibited nonlinear kinetics following the priming dose regimens. AUC last was 175.6, 713.8, 2040.6, 2181.6, and 3829.2 mcg⋅h/mL following doses of 1, 2, 3.75, 4, and 5.5 g/m 2 , respectively. The total clearance decreased from 1.82 to 0.89 mcg⋅h/mL with increasing dose (3.75 and 4 g/m 2 , respectively). During the sequence of 90 minute priming infusion followed by a 24 hour maintenance infusion, phenylacetate was detected in the plasma at the end of infusion (T max of 2 hr at 3.75 g/m 2 ) whereas, benzoate concentrations declined rapidly (T max of 1.5 hr at 3.75 g/m 2 ) and were undetectable at 14 and 26 hours following the 3.75 and 4 g/m 2 dose, respectively. A difference in the metabolic rates for phenylacetate and benzoate was noted. The formation of hippurate from benzoate occurred more rapidly than that of phenylacetylglutamine from phenylacetate, and the rate of elimination for hippurate appeared to be more rapid than that for phenylacetylglutamine. Pharmacokinetic observations have also been reported from twelve episodes of hyperammonemic encephalopathy in seven children diagnosed (age 3 to 26 months) with urea cycle disorders who had been administered Sodium Phenylacetate and Sodium Benzoate Injection intravenously. These data showed peak plasma levels of phenylacetate and benzoate at approximately the same times as were observed in healthy adults. As in healthy adults, the plasma levels of phenylacetate were higher than benzoate and were present for a longer time. The pharmacokinetics of intravenous phenylacetate have been reported following administration to adult patients with advanced solid tumors. The decline in serum phenylacetate concentrations following a loading infusion of 150 mg/kg was consistent with saturable enzyme kinetics. Ninety-nine percent of administered phenylacetate was excreted as phenylacetylglutamine."],"adverse_reactions":["6 ADVERSE REACTIONS The most frequently reported adverse reactions (incidence ≥ 6%) are vomiting, hyperglycemia, hypokalemia, convulsions, and mental impairment. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals USA Inc. Pennington, NJ 08534 at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety data were obtained from 316 patients who received Sodium Phenylacetate and Sodium Benzoate Injection as emergency (rescue) or prospective treatment for hyperammonemia as part of an uncontrolled, open-label study. The study population included patients between the ages of 0 to 53 years with a mean (SD) of 6.2 (8.54) years; 51% were male and 49% were female who had the following diagnoses: OTC (46%), ASS (22%), CPS (12%), ASL (2%), ARG (<1%), THN (<1%), and other (18%). Adverse reactions were reported with similar frequency in patients with OTC, ASS, CPS, and diagnoses categorized as \"other.\" Nervous system disorders were more frequent in patients with OTC and CPS, compared with patients with ASS and patients with \"other\" diagnoses. Convulsions and mental impairment were reported in patients with OTC and CPS. These observations are consistent with literature reports that patients with enzyme deficiencies occurring earlier in the urea cycle (i.e., OTC and CPS) tend to be more severely affected. Adverse reactions profiles differed by age group. Patients ≤30 days of age had more blood and lymphatic system disorders and vascular disorders (specifically hypotension), while patients > 30 days of age had more gastrointestinal disorders (specifically nausea, vomiting and diarrhea). Less common adverse reactions (<3% of patients) that are characterized as severe are listed below by body system. BLOOD AND LYMPHATIC SYSTEM DISORDERS: coagulopathy, pancytopenia, thrombocytopenia. CARDIAC DISORDERS: atrial rupture, bradycardia, cardiac or cardiopulmonary arrest/failure, cardiogenic shock, cardiomyopathy, pericardial effusion. EYE DISORDERS: blindness. GASTROINTESTINAL DISORDERS: abdominal distension, gastrointestinal hemorrhage. GENERAL DISORDERS AND ADMINISTRATION-SITE CONDITIONS: asthenia, brain death, chest pain, multiorgan failure, edema. HEPATOBILIARY DISORDERS: cholestasis, hepatic artery stenosis, hepatic failure/hepatotoxicity, jaundice. INFECTIONS AND INFESTATIONS: sepsis/septic shock. INJURY, POISONING AND PROCEDURAL COMPLICATIONS: brain herniation, subdural hematoma, overdose. INVESTIGATIONS: blood carbon dioxide changes, blood glucose changes, blood pH increased, cardiac output decreased, pCO 2 changes, respiratory rate increased. METABOLISM AND NUTRITION DISORDERS: alkalosis, dehydration, fluid overload/retention, hypoglycemia, hyperkalemia, hypernatremia, alkalosis, tetany. NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED: hemangioma acquired. NERVOUS SYSTEM DISORDERS: areflexia, ataxia, brain infarction, brain hemorrhage, cerebral atrophy, clonus, depressed level of consciousness, encephalopathy, nerve paralysis, intracranial pressure increased, subdural hematoma, tremor. PSYCHIATRIC DISORDERS: acute psychosis, aggression, confusional state, hallucinations. RENAL AND URINARY DISORDERS: anuria, renal failure, urinary retention. RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS: acute respiratory distress syndrome, dyspnea, hypercapnia, hyperventilation, Kussmaul respiration, pneumonia aspiration, pneumothorax, pulmonary hemorrhage, pulmonary edema, respiratory acidosis or alkalosis, respiratory arrest/failure. SKIN AND SUBCUTANEOUS TISSUE DISORDERS: alopecia, blister, pruritus generalized, rash, urticarial. VASCULAR DISORDERS: flushing, hemorrhage, hypertension, phlebothrombosis/thrombosis. Table 2 : Adverse Reactions Occurring in ≥3% of Patients Treated with Sodium Phenylacetate and Sodium Benzoate Injection Patients N=316 Number of patients with any adverse event 163 (52%) Blood and lymphatic system disorders 35 (11%) Anemia 12 (4%) Disseminated intravascular coagulation 11 (3%) Cardiac disorders 28 (9%) Gastrointestinal disorders 42 (13%) Diarrhea 10 (3%) Nausea 9 (3%) Vomiting 29 (9%) General disorders and administration-site conditions 45 (14%) Injection-site reaction 11 (3%) Pyrexia 17 (5%) Infections 39 (12%) Urinary tract infection 9 (3%) Injury, poisoning and procedural complications 12 (4%) Investigations 32 (10%) Metabolism and nutrition disorders 67 (21%) Acidosis 8 (3%) Hyperammonemia 17 (5%) Hyperglycemia 22 (7%) Hypocalcemia 8 (3%) Hypokalemia 23 (7%) Metabolic acidosis 13 (4%) Nervous system disorders 71 (22%) Brain edema 17 (5%) Coma 10 (3%) Convulsions 19 (6%) Mental impairment 18 (6%) Psychiatric disorders 16 (5%) Agitation 8 (3%) Renal and urinary disorders 14 (4%) Respiratory, thoracic and mediastinal disorders 47 (15%) Respiratory distress 9 (3%) Skin and subcutaneous tissue disorders 19 (6%) Vascular disorders 19 (6%) Hypotension 14 (4%)"],"contraindications":["4 CONTRAINDICATIONS None ( 4 ) None."],"drug_interactions":["7 DRUG INTERACTIONS Some antibiotics such as penicillin may affect the overall disposition of the infused drug. ( 7 ) Probenecid may affect renal excretion of phenylacetylglutamine and hippurate. ( 7 ) Valproic acid given to patients with urea cycle disorders may exacerbate their condition and antagonize the efficacy of Sodium Phenylacetate and Sodium Benzoate Injection through inhibition of the synthesis of N-acetylglutamate, a co-factor for carbamyl phosphate synthetase. ( 7 ) Use of corticosteroids may cause the breakdown of body protein and potentially increase plasma ammonia levels in patients with impaired ability to form urea. ( 7 ) Formal drug interaction studies have not been performed with Sodium Phenylacetate and Sodium Benzoate Injection. Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. Probenecid is known to inhibit the renal transport of many organic compounds, including aminohippuric acid, and may affect renal excretion of phenylacetylglutamine and hippurate. There have been reports that valproic acid can induce hyperammonemia through inhibition of the synthesis of N -acetylglutamate, a co-factor for carbamyl phosphate synthetase. Therefore, administration of valproic acid to patients with urea cycle disorders may exacerbate their condition and antagonize the efficacy of Sodium Phenylacetate and Sodium Benzoate Injection. Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea."],"mechanism_of_action":["12.1 Mechanism of Action Urea cycle disorders can result from decreased activity of any of the following enzymes: N -acetylglutamate synthetase (NAGS), carbamyl phosphate synthetase (CPS), argininosuccinate synthetase (ASS), ornithine transcarbamylase (OTC), argininosuccinate lyase (ASL), or arginase (ARG). Sodium phenylacetate and sodium benzoate are metabolically active compounds that can serve as alternatives to urea for the excretion of waste nitrogen. Figure 2 is a schematic illustrating how the components of Sodium Phenylacetate and Sodium Benzoate Injection, phenylacetate and benzoate, provide an alternative pathway for nitrogen disposal in patients without a fully functioning urea cycle. Phenylacetate conjugates with glutamine in the liver and kidneys to form phenylacetylglutamine, via acetylation. Phenylacetylglutamine is excreted by the kidneys via glomerular filtration and tubular secretion. The nitrogen content of phenylacetylglutamine per mole is identical to that of urea (both contain two moles of nitrogen). Two moles of nitrogen are removed per mole of phenylacetate when it is conjugated with glutamine. Similarly, preceded by acylation, benzoate conjugates with glycine to form hippuric acid, which is rapidly excreted by the kidneys by glomerular filtration and tubular secretion. One mole of hippuric acid contains one mole of waste nitrogen. Thus, one mole of nitrogen is removed per mole of benzoate when it is conjugated with glycine. Figure 2 CPS = carbamyl phosphate synthetase; OTC = ornithine transcarbamylase; ASS = argininosuccinate synthetase; ASL = argininosuccinate lyase; ARG = arginase; NAGS = N -acetylglutamate synthetase"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Urea cycle disorders can result from decreased activity of any of the following enzymes: N -acetylglutamate synthetase (NAGS), carbamyl phosphate synthetase (CPS), argininosuccinate synthetase (ASS), ornithine transcarbamylase (OTC), argininosuccinate lyase (ASL), or arginase (ARG). Sodium phenylacetate and sodium benzoate are metabolically active compounds that can serve as alternatives to urea for the excretion of waste nitrogen. Figure 2 is a schematic illustrating how the components of Sodium Phenylacetate and Sodium Benzoate Injection, phenylacetate and benzoate, provide an alternative pathway for nitrogen disposal in patients without a fully functioning urea cycle. Phenylacetate conjugates with glutamine in the liver and kidneys to form phenylacetylglutamine, via acetylation. Phenylacetylglutamine is excreted by the kidneys via glomerular filtration and tubular secretion. The nitrogen content of phenylacetylglutamine per mole is identical to that of urea (both contain two moles of nitrogen). Two moles of nitrogen are removed per mole of phenylacetate when it is conjugated with glutamine. Similarly, preceded by acylation, benzoate conjugates with glycine to form hippuric acid, which is rapidly excreted by the kidneys by glomerular filtration and tubular secretion. One mole of hippuric acid contains one mole of waste nitrogen. Thus, one mole of nitrogen is removed per mole of benzoate when it is conjugated with glycine. Figure 2 CPS = carbamyl phosphate synthetase; OTC = ornithine transcarbamylase; ASS = argininosuccinate synthetase; ASL = argininosuccinate lyase; ARG = arginase; NAGS = N -acetylglutamate synthetase 12.2 Pharmacodynamics In patients with hyperammonemia due to deficiencies in enzymes of the urea cycle, Sodium Phenylacetate and Sodium Benzoate Injection has been shown to decrease elevated plasma ammonia levels. These effects are considered to be the result of reduction in nitrogen overload through glutamine and glycine scavenging by Sodium Phenylacetate and Sodium Benzoate Injection in combination with appropriate dietary and other supportive measures. 12.3 Pharmacokinetics The pharmacokinetics of intravenously administered Sodium Phenylacetate and Sodium Benzoate Injection was characterized in healthy adult volunteers. Both benzoate and phenylacetate exhibited nonlinear kinetics. Following 90 minute intravenous infusion mean AUC last for benzoate was 20.3, 114.9, 564.6, 562.8, and 1599.1 mcg/mL following doses of 1, 2, 3.75, 4, and 5.5 g/m 2 , respectively. The total clearance decreased from 5.19 to 3.62 L/h/m 2 at the 3.75 and 5.5 g/m 2 doses, respectively. Similarly, phenylacetate exhibited nonlinear kinetics following the priming dose regimens. AUC last was 175.6, 713.8, 2040.6, 2181.6, and 3829.2 mcg⋅h/mL following doses of 1, 2, 3.75, 4, and 5.5 g/m 2 , respectively. The total clearance decreased from 1.82 to 0.89 mcg⋅h/mL with increasing dose (3.75 and 4 g/m 2 , respectively). During the sequence of 90 minute priming infusion followed by a 24 hour maintenance infusion, phenylacetate was detected in the plasma at the end of infusion (T max of 2 hr at 3.75 g/m 2 ) whereas, benzoate concentrations declined rapidly (T max of 1.5 hr at 3.75 g/m 2 ) and were undetectable at 14 and 26 hours following the 3.75 and 4 g/m 2 dose, respectively. A difference in the metabolic rates for phenylacetate and benzoate was noted. The formation of hippurate from benzoate occurred more rapidly than that of phenylacetylglutamine from phenylacetate, and the rate of elimination for hippurate appeared to be more rapid than that for phenylacetylglutamine. Pharmacokinetic observations have also been reported from twelve episodes of hyperammonemic encephalopathy in seven children diagnosed (age 3 to 26 months) with urea cycle disorders who had been administered Sodium Phenylacetate and Sodium Benzoate Injection intravenously. These data showed peak plasma levels of phenylacetate and benzoate at approximately the same times as were observed in healthy adults. As in healthy adults, the plasma levels of phenylacetate were higher than benzoate and were present for a longer time. The pharmacokinetics of intravenous phenylacetate have been reported following administration to adult patients with advanced solid tumors. The decline in serum phenylacetate concentrations following a loading infusion of 150 mg/kg was consistent with saturable enzyme kinetics. Ninety-nine percent of administered phenylacetate was excreted as phenylacetylglutamine. moa-figure-02"],"indications_and_usage":["1 INDICATIONS AND USAGE Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in paediatric and adult patients with deficiencies in enzymes of the urea cycle. ( 1 ) Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Decreased Potassium Levels: Plasma potassium levels should be carefully monitored and appropriate treatment given when necessary. ( 5.1 ) Conditions Associated with Fluid Overload: Sodium Phenylacetate and Sodium Benzoate Injection contains 30.5 mg of sodium per mL of undiluted product. Caution should be used if Sodium Phenylacetate and Sodium Benzoate Injection is administered to patients with congestive heart failure, severe renal insufficiency, or with conditions in which there is sodium retention with edema. ( 5.2 ) Extravasation: Extravasation of Sodium Phenylacetate and Sodium Benzoate Injection into the perivenous tissues during high flow bolus infusion may lead to skin necrosis, especially in infants. The infusion site must be monitored closely for possible tissue infiltration during drug administration. ( 5.3 ) Neurotoxicity of Phenylacetate: Because of prolonged plasma levels achieved by phenylacetate in pharmacokinetic studies, repeat loading doses should not be administered. Additionally, neurotoxicity related to phenylacetate has been reported in cancer patients. Monitor patients for symptoms of acute neurotoxicity.( 5.4 ) Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. Monitor patient blood chemistry profiles and perform frequent blood pH and pCO 2 measurements. ( 5.5 ) 5.1 Decreased Potassium Levels Because urine potassium loss is enhanced by the excretion of the non-reabsorbable anions, phenylacetylglutamine and hippurate, plasma potassium levels should be carefully monitored and appropriate treatment given when necessary. 5.2 Conditions Associated with Fluid Overload Sodium Phenylacetate and Sodium Benzoate Injection contains 30.5 mg of sodium per mL of undiluted product. Thus, Sodium Phenylacetate and Sodium Benzoate Injection should be used with great care, if at all, in patients with congestive heart failure or severe renal insufficiency, and in clinical states in which there is sodium retention with edema. Discontinue administration of Sodium Phenylacetate and Sodium Benzoate Injection, evaluate the patient, and institute appropriate therapeutic countermeasures if an adverse event occurs. 5.3 Extravasation Administration must be through a central venous catheter. Administration through a peripheral line may cause burns . Bolus infusion flow rates are relatively high, especially for infants [ see Dosage and Administration (2) ]. Extravasation of Sodium Phenylacetate and Sodium Benzoate Injection into the perivenous tissues may lead to skin necrosis. If extravasation is suspected, discontinue the infusion and resume at a different infusion site, if necessary. The infusion site must be monitored closely for possible infiltration during drug administration. Do not administer undiluted product. 5.4 Neurotoxicity of Phenylacetate Because of prolonged plasma levels achieved by phenylacetate in pharmacokinetic studies, repeat loading doses of Sodium Phenylacetate and Sodium Benzoate Injection should not be administered. Additionally, neurotoxicity was reported in cancer patients receiving intravenous phenylacetate, 250–300 mg/kg/day for 14 days, repeated at 4-week intervals. Manifestations were predominantly somnolence, fatigue, and lightheadedness, with less frequent headaches, dysgeusia, hypoacusis, disorientation, impaired memory, and exacerbation of a pre-existing neuropathy. The acute onset of symptoms upon initiation of treatment and reversibility of symptoms when the phenylacetate was discontinued suggest a drug effect [ See Animal Toxicology and/or Pharmacology (13.2) ]. 5.5 Hyperventilation and Metabolic Acidosis Due to structural similarities between phenylacetate and benzoate to salicylate, Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. Monitoring of blood chemistry profiles, blood pH and pCO 2 should be performed."],"clinical_studies_table":["
Table 3: Baseline Characteristics and Diagnoses of Study Population
OTC = ornithine transcarbamylase deficiency
ASS = argininosuccinate synthetase deficiency
CPS = carbamyl phosphate synthetase deficiency
ASL = argininosuccinate lyase deficiency
ARG = arginase deficiency
THN = transient hyperammonemia of the newborn
*For the summary at the patient level, data obtained at first episode used.
**Diagnosis unknown or pending (33 episodes), acidemia (14 episodes), HHH syndrome (6 episodes), carnitine translocase deficiency (4 episodes), liver disease (3 episodes), HMG CoA lyase deficiency (1 episode), non-ketotic hyperglycinemia (1 episode), suspected fatty acid oxidation deficiency (1 episode), and valproic-acid-induced hyperammonemia (1 episode).
Patients* N=316
Gender Male 158 (51%)
Female 150 (49%)
N 310
Age (years) Mean (SD) 6.2 (8.54)
Min–Max 0.0–53.0
0–30 days 104 (34%)
31 days–2 years 55 (18%)
Age groups > 2–12 years 90 (29%)
> 12–16 years 30 (10%)
> 16 years 31 (10%)
OTC 146 (46%)
ASS 71 (22%)
CPS 38 (12%)
Enzyme deficiency ASL 7 (2%)
ARG 2 (< 1%)
THN 2 (< 1%)
Other** 56 (18%)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals have not been performed to evaluate the carcinogenic potential of Sodium Phenylacetate and Sodium Benzoate Injection. Studies to evaluate the possible impairment of fertility or mutagenic potential of Sodium Phenylacetate and Sodium Benzoate Injection have not been performed. Results indicate that sodium benzoate is not mutagenic or carcinogenic and does not impair fertility. 13.2 Animal Toxicology and/or Pharmacology In animal studies, subcutaneous administration to rat pups of 190–474 mg/kg of phenylacetate caused decreased proliferation and increased loss of neurons, and reduced central nervous system (CNS) myelin. Cerebral synapse maturation was retarded, and the number of functioning nerve terminals in the cerebrum was reduced, which resulted in impaired brain growth. Pregnant rats were given phenylacetate at 3.5 μmol/g/day subcutaneously from gestation day 7 through normal delivery. Prenatal exposure of rat pups to phenylacetate produced lesions in layer 5 cortical pyramidal cells; dendritic spines were longer and thinner than normal and reduced in number."],"adverse_reactions_table":["
Table 2 : Adverse Reactions Occurring in ≥3% of Patients Treated with Sodium Phenylacetate and Sodium Benzoate Injection
Patients N=316
Number of patients with any adverse event 163 (52%)
Blood and lymphatic system disorders 35 (11%)
Anemia 12 (4%)
Disseminated intravascular coagulation 11 (3%)
Cardiac disorders 28 (9%)
Gastrointestinal disorders 42 (13%)
Diarrhea 10 (3%)
Nausea 9 (3%)
Vomiting 29 (9%)
General disorders and administration-site conditions 45 (14%)
Injection-site reaction 11 (3%)
Pyrexia 17 (5%)
Infections 39 (12%)
Urinary tract infection 9 (3%)
Injury, poisoning and procedural complications 12 (4%)
Investigations 32 (10%)
Metabolism and nutrition disorders 67 (21%)
Acidosis 8 (3%)
Hyperammonemia 17 (5%)
Hyperglycemia 22 (7%)
Hypocalcemia 8 (3%)
Hypokalemia 23 (7%)
Metabolic acidosis 13 (4%)
Nervous system disorders 71 (22%)
Brain edema 17 (5%)
Coma 10 (3%)
Convulsions 19 (6%)
Mental impairment 18 (6%)
Psychiatric disorders 16 (5%)
Agitation 8 (3%)
Renal and urinary disorders 14 (4%)
Respiratory, thoracic and mediastinal disorders 47 (15%)
Respiratory distress 9 (3%)
Skin and subcutaneous tissue disorders 19 (6%)
Vascular disorders 19 (6%)
Hypotension 14 (4%)
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Physicians should advise patients and caregivers about the following for safe use of Sodium Phenylacetate and Sodium Benzoate Injection: When plasma ammonia levels have normalized, dietary protein intake can usually be increased with the goal of unrestricted protein intake. The most common adverse reactions are vomiting, hyperglycemia, hypokalemia, convulsions, and mental impairment. Generally BUPHENYL is stopped during the time Sodium Phenylacetate and Sodium Benzoate Injection is used."],"spl_unclassified_section":["Distributed by: Zydus Pharmaceuticals USA Inc. Pennington NJ 08534 30190323 R0"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Sodium Phenylacetate and Sodium Benzoate Injection must be diluted with sterile 10% Dextrose Injection (D10W) before administration. Administration must be through a central venous catheter. Administration through a peripheral line may cause burns. ( 2 ) Sodium Phenylacetate and Sodium Benzoate Injection is administered intravenously as a loading dose infusion administered over 90 to 120 minutes, followed by an equivalent maintenance dose infusion administered over 24 hours. ( 2 ) See Full Prescribing Information for complete dosing recommendations. 2.1 Recommended Dosage Sodium Phenylacetate and Sodium Benzoate Injection must be diluted with sterile 10% Dextrose Injection (D10W) before administration. The dilution and dosage of Sodium Phenylacetate and Sodium Benzoate Injection are determined by weight for neonates, infants and young children, and by body surface area for larger patients, including older children, adolescents, and adults (Table 1). Table 1: Dosage and Administration Abbreviations: CPS - carbamyl phosphate synthetase; OTC - ornithine transcarbamylase; ASS - argininosuccinate synthetase; ASL - argininosuccinate lyase Patient Population Components of Infusion Solution Sodium Phenylacetate and Sodium Benzoate Injection must be diluted with sterile 10% Dextrose Injection at ≥ 25 mL/Kg before administration. Dosage Provided Sodium Phenylacetate and Sodium Benzoate Injection Arginine HCl Injection, 10% Sodium Phenylacetate Sodium Benzoate Arginine HCl CPS and OTC Deficiency Patients 0 to 20 kg: Dose Loading: over 90 to 120 minutes Maintenance: over 24 hours 2.5 mL/kg 2 mL/kg 250 mg/kg 250 mg/kg 200 mg/kg ASS and ASL Deficiency Dose Loading: over 90 to 120 minutes Maintenance: over 24 hours 2.5 mL/kg 6 mL/kg 250 mg/kg 250 mg/kg 600 mg/kg CPS and OTC Deficiency Patient>20kg: Dose Loading: over 90 to 120 minutes Maintenance: over 24 hours 55 mL/m 2 2 mL/kg 5.5g/m 2 5.5 g/m 2 200 mg/kg ASS and ASL Deficiency Dose Loading: over 90 to 120 minutes Maintenance: over 24 hours 55 mL/m 2 6 mL/kg 5.5 g/m 2 5.5 g/m 2 600 mg/kg 2.2 Administration Sodium Phenylacetate and Sodium Benzoate Injection is a concentrated solution and must be diluted before intravenous administration via a central venous catheter. Administration through a peripheral intravenous catheter may cause burns. Sodium Phenylacetate and Sodium Benzoate Injection may not be administered by any other route. Sodium Phenylacetate and Sodium Benzoate Injection should be administered as a loading dose infusion over 90 to 120 minutes, followed by the same dose repeated as a maintenance infusion administered over 24 hours. Because of prolonged plasma levels achieved by phenylacetate in pharmacokinetic studies, repeat loading doses of Sodium Phenylacetate and Sodium Benzoate Injection should not be administered. Maintenance infusions may be continued until elevated plasma ammonia levels have been normalized or the patient can tolerate oral nutrition and medications. An antiemetic may be administered during Sodium Phenylacetate and Sodium Benzoate Injection infusion to aid control of infusion-associated nausea and vomiting. Administration of analogous oral drugs, such as sodium phenylbutyrate, should be terminated prior to Sodium Phenylacetate and Sodium Benzoate Injection infusion. Sodium Phenylacetate and Sodium Benzoate Injection infusion should be started as soon as the diagnosis of hyperammonemia is made. Treatment of hyperammonemia also requires caloric supplementation and restriction of dietary protein. Non-protein calories should be supplied principally as glucose (8–10 mg/kg/min) with an intravenous fat emulsion added. Attempts should be made to maintain a caloric intake of greater than 80 kcal/kg/day. During and after infusion of Sodium Phenylacetate and Sodium Benzoate Injection, ongoing monitoring of the following clinical laboratory values is crucial: plasma ammonia, glutamine, quantitative plasma amino acids, blood glucose, electrolytes, venous or arterial blood gases, AST and ALT. On-going monitoring of the following clinical responses is also crucial to assess patient response to treatment: neurological status, Glasgow Coma Scale, tachypnea, CT or MRI scan or fundoscopic evidence of cerebral edema, and/or of gray matter and white matter damage. Hemodialysis should be considered in patients with severe hyperammonemia or who are not responsive to Sodium Phenylacetate and Sodium Benzoate Injection administration [ see Warnings and Precautions (5.1) ]. In the non-neonatal study patient population treated with Sodium Phenylacetate and Sodium Benzoate Injection, dialysis was required in 13% of hyperammonemic episodes. Standard hemodialysis was the most frequently used dialysis method. High levels of ammonia can be reduced quickly when Sodium Phenylacetate and Sodium Benzoate Injection is used with hemodialysis, as the ammonia-scavenging of Sodium Phenylacetate and Sodium Benzoate Injection suppresses the production of ammonia from catabolism of endogenous protein and hemodialysis eliminates the ammonia and ammonia conjugates. Sodium Phenylacetate and Sodium Benzoate Injection solutions are physically and chemically stable for up to 24 hours at room temperature and room lighting conditions. No compatibility information is presently available for Sodium Phenylacetate and Sodium Benzoate Injection infusion solutions except for Arginine HCl Injection, 10%, which may be mixed in the same container as Sodium Phenylacetate and Sodium Benzoate Injection. Other infusion solutions and drug products should not be administered together with Sodium Phenylacetate and Sodium Benzoate Injection infusion solution. Sodium Phenylacetate and Sodium Benzoate Injection solutions may be prepared in glass and PVC containers. Arginine Administration Intravenous arginine is an essential component of therapy for patients with carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC), argininosuccinate synthetase (ASS), or argininosuccinate lyase (ASL) deficiency. Because hyperchloremic acidosis may develop after high-dose arginine hydrochloride administration, chloride and bicarbonate levels should be monitored and appropriate amounts of bicarbonate administered. In hyperammonemic infants with suspected, but unconfirmed urea cycle disorders, intravenous arginine should be given (6 mL/kg of Arginine HCl Injection 10%, over 90 minutes followed by the same dose given as a maintenance infusion over 24 hours). If deficiencies of ASS or ASL are excluded as diagnostic possibilities, the intravenous dose of arginine HCl should be reduced to 2 mL/kg/day Arginine HCl Injection 10%. Converting To Oral Treatment Once elevated ammonia levels have been reduced to the normal range, oral therapy, such as sodium phenylbutyrate, dietary management and maintenance protein restrictions should be started or reinitiated."],"spl_product_data_elements":["Sodium phenylacetate and Sodium benzoate Sodium phenylacetate and Sodium benzoate SODIUM PHENYLACETATE PHENYLACETIC ACID SODIUM BENZOATE BENZOIC ACID WATER SODIUM HYDROXIDE HYDROCHLORIC ACID"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Injection: 10% per 10% sterile, concentrated, aqueous solution of sodium phenylacetate and sodium benzoate. ( 3 ) Sodium Phenylacetate and Sodium Benzoate Injection 10% per 10% is a sterile, clear and almost colorless concentrated, aqueous solution of sodium phenylacetate and sodium benzoate."],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Available data on the combination use of Sodium Phenylacetate and Sodium Benzoate in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with Sodium Phenylacetate and Sodium Benzoate Injection. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. 8.2 Lactation Risk Summary There are no data on the presence of sodium phenylacetate, sodium benzoate in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Sodium Phenylacetate and Sodium Benzoate Injection and any potential adverse effects on the breastfed infant from Sodium Phenylacetate and Sodium Benzoate Injection or from the underlying maternal condition. 8.4 Pediatric Use Sodium Phenylacetate and Sodium Benzoate Injection has been used as a treatment for acute hyperammonemia in pediatric patients including patients in the early neonatal period [ see Dosage and Administration (2) ]. 8.5 Geriatric Use Clinical studies of Sodium Phenylacetate and Sodium Benzoate Injection did not include any patients aged 65 and over to determine whether they respond differently from younger patients. Urea cycle disorders are presently diseases of the pediatric and younger adult populations. No pharmacokinetic studies of Sodium Phenylacetate and Sodium Benzoate Injection have been performed in geriatric patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy in this patient population. 8.6 Gender Pharmacokinetic parameters of Sodium Phenylacetate and Sodium Benzoate Injection were compared in healthy males and females. Bioavailability of both benzoate and phenylacetate was slightly higher in females than in males. However, conclusions cannot be drawn due to the limited number of subjects in this study. 8.7 Hepatic Insufficiency Limited information is available on the metabolism and excretion of sodium phenylacetate and sodium benzoate in patients with impaired hepatic function. However, metabolic conjugation of sodium phenylacetate and sodium benzoate is known to take place in the liver and kidney. Therefore, caution should be used in administering Sodium Phenylacetate and Sodium Benzoate Injection to patients with hepatic insufficiency. 8.8 Renal Impairment The drug metabolites of Sodium Phenylacetate and Sodium Benzoate Injection (phenylacetylglutamine and hippurate) and subsequently ammonia are primarily excreted by the kidney. Therefore, use caution and closely monitor patients with impaired renal function who receive Sodium Phenylacetate and Sodium Benzoate Injection."],"dosage_and_administration_table":["
Table 1: Dosage and Administration
Abbreviations: CPS - carbamyl phosphate synthetase; OTC - ornithine transcarbamylase; ASS - argininosuccinate synthetase; ASL - argininosuccinate lyase
Patient Population Components of Infusion Solution Sodium Phenylacetate and Sodium Benzoate Injection must be diluted with sterile 10% Dextrose Injection at ≥ 25 mL/Kg before administration. Dosage Provided
Sodium Phenylacetate and Sodium Benzoate Injection Arginine HCl Injection, 10% Sodium Phenylacetate Sodium Benzoate Arginine HCl
CPS and OTC Deficiency
Patients 0 to 20 kg: Dose Loading: over 90 to 120 minutes Maintenance: over 24 hours 2.5 mL/kg 2 mL/kg 250 mg/kg 250 mg/kg 200 mg/kg
ASS and ASL Deficiency
Dose Loading: over 90 to 120 minutes Maintenance: over 24 hours 2.5 mL/kg 6 mL/kg 250 mg/kg 250 mg/kg 600 mg/kg
CPS and OTC Deficiency
Patient>20kg: Dose Loading: over 90 to 120 minutes Maintenance: over 24 hours 55 mL/m2 2 mL/kg 5.5g/m2 5.5 g/m2 200 mg/kg
ASS and ASL Deficiency
Dose Loading: over 90 to 120 minutes Maintenance: over 24 hours 55 mL/m2 6 mL/kg 5.5 g/m2 5.5 g/m2 600 mg/kg
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL Vial Carton vial-label carton-label"]},"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"Penicillin","severity":"moderate","mechanism":"May compete with phenylacetylglutamine and hippurate for active secretion by renal tubules","management":"Monitor drug levels and adjust dosing if necessary","clinicalEffect":"May affect the overall disposition of the infused drug"},{"drug":"Probenecid","severity":"moderate","mechanism":"Inhibits renal transport of many organic compounds, including phenylacetylglutamine and hippurate","management":"Monitor renal function and drug levels; consider alternative therapies if significant interaction occurs","clinicalEffect":"May affect renal excretion of phenylacetylglutamine and hippurate"},{"drug":"Valproic Acid","severity":"major","mechanism":"Inhibits the synthesis of N-acetylglutamate, a co-factor for carbamyl phosphate synthetase","management":"Avoid concomitant use in patients with urea cycle disorders; monitor closely for signs of hyperammonemia","clinicalEffect":"May exacerbate urea cycle disorders and antagonize the efficacy of Sodium Phenylacetate and Sodium Benzoate Injection"},{"drug":"Corticosteroids","severity":"moderate","mechanism":"Cause a protein catabolic state","management":"Monitor plasma ammonia levels and liver function; adjust corticosteroid dose or discontinue if necessary","clinicalEffect":"May increase plasma ammonia levels in patients with impaired ability to form urea"}],"commonSideEffects":[{"effect":"vomiting","drugRate":"9%","_validated":true,"placeboRate":""},{"effect":"hyperglycemia","drugRate":"7%","_validated":true,"placeboRate":""},{"effect":"hypokalemia","drugRate":"7%","_validated":true,"placeboRate":""},{"effect":"convulsions","drugRate":"6%","_validated":true,"placeboRate":""},{"effect":"mental impairment","drugRate":"6%","_validated":true,"placeboRate":""}]},"_chembl":{"chemblId":"CHEMBL1200358","moleculeType":"Small molecule","molecularWeight":"158.13"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=SODIUM PHENYLACETATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:58:03.099351+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T03:59:06.508130+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:58:08.726175+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SODIUM PHENYLACETATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:58:09.010931+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:58:01.989842+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:59:01.334518+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:58:01.989871+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action Urea cycle disorders can result from decreased activity of any of the following enzymes: N -acetylglutamate synthetase (NAGS), carbamyl phosphate synthetase (CPS), argininosuccinate synthetase (ASS), ornithine transcarbamylase (OTC), argininosuccinate lyase (ASL), or arginase (ARG). Sodium phenylacetate and sodium benzoate are metabolically active compounds that can serve as alternatives to urea for the excretion of waste nitrogen. Figure 2 is a schematic illustrating ho","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:58:23.160274+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glutamine sequestering agent","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:58:10.791213+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:58:52.981134+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200358/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:58:10.436587+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS The most frequently reported adverse reactions (incidence ≥ 6%) are vomiting, hyperglycemia, hypokalemia, convulsions, and mental impairment. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals USA Inc. Pennington, NJ 08534 at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a dru","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:58:31.418611+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA217526","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:58:01.989875+00:00"}},"_dailymed":{"setId":"d20768fe-4516-483a-a082-ff1df9ad1d99","title":"SODIUM PHENYLACETATE AND SODIUM BENZOATE INJECTION, SOLUTION, CONCENTRATE [NAVINTA LLC]"},"aiSummary":"Sodium phenylacetate is a small molecule that acts as a glutamine sequestering agent. It has been studied in clinical trials for various conditions, including inflammation, acute pancreatitis, low back pain, renal insufficiency, and hepatic insufficiency.","mechanism":{"modality":"Small molecule","explanation":"In patients with urea cycle disorders, sodium phenylacetate and sodium benzoate help remove waste nitrogen through alternative metabolic pathways. Phenylacetate forms phenylacetylglutamine, which is excreted by the kidneys, while benzoate forms hippuric acid, also excreted by the kidneys.","oneSentence":"Sodium phenylacetate and sodium benzoate provide alternative pathways for nitrogen disposal in patients with urea cycle disorders.","technicalDetail":"Phenylacetate conjugates with glutamine in the liver and kidneys to form phenylacetylglutamine, which is excreted via glomerular filtration and tubular secretion. Benzoate conjugates with glycine to form hippuric acid, which is also excreted by the kidneys."},"_scrapedAt":"2026-03-27T23:37:51.225Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T03:59:06.508473+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"id":"sodium-phenylacetate-acute-hyperammonemia-and-assoc","name":"Acute hyperammonemia and associated encephalopathy","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Paediatric and adult patients with deficiencies in enzymes of the urea cycle","pivotalTrial":null,"restrictions":[],"patientPopulation":"Paediatric and adult patients with deficiencies in enzymes of the urea cycle","diagnosticRequired":null,"brandNameForIndication":""}]},"trialDetails":[{"nctId":"NCT07475663","phase":"PHASE3","title":"Counterpain PXM Versus Diclofenac Versus Piroxicam","status":"COMPLETED","sponsor":"Taisho Pharmaceutical Indonesia","startDate":"2025-11-04","conditions":"Ankle Sprain, Back Pain, Osteoarthritis (OA) of the Knee","enrollment":180},{"nctId":"NCT07079969","phase":"PHASE2","title":"Effects of Photobiomodulation and Topical Diclofenac on Inflammation and Pain in Knee Osteoarthritis (EPIC-KO)","status":"NOT_YET_RECRUITING","sponsor":"University of Florida","startDate":"2026-04","conditions":"Knee Pain Chronic","enrollment":32},{"nctId":"NCT07379762","phase":"PHASE4","title":"Intramuscular Versus Rectal Diclofenac for Pain Relief After Cesarean Section in Women","status":"COMPLETED","sponsor":"CMH Multan Institute of Medical Sciences","startDate":"2025-02-01","conditions":"Cesarean Section Pain, Diclofenac, Suppository","enrollment":60},{"nctId":"NCT07304882","phase":"PHASE3","title":"A Comparison of Recovery After Impacted Wisdom Tooth Removal","status":"COMPLETED","sponsor":"University of Science and Technology, Yemen","startDate":"2023-11-30","conditions":"Impacted Mandibular Third Molar Extraction, Post Operative Complications","enrollment":24},{"nctId":"NCT06942702","phase":"NA","title":"Efficacy of Genicular Block on Total Knee Arthroplasty Surgery","status":"NOT_YET_RECRUITING","sponsor":"Mersin University","startDate":"2025-12-20","conditions":"Total Knee Anthroplasty, Genicular Nerves Block","enrollment":44},{"nctId":"NCT07267182","phase":"NA","title":"Gabapentin and Diclofenac Sodium Comparison for Post-Operative Pain Relief","status":"COMPLETED","sponsor":"Muhammad Aamir Latif","startDate":"2022-08-01","conditions":"Postoperative Pain","enrollment":240},{"nctId":"NCT07237620","phase":"NA","title":"The Effect of Different Intracanal Medicaments on Periapical Lesion Healing","status":"RECRUITING","sponsor":"Mustafa Kemal University","startDate":"2025-09-15","conditions":"Periapical Lesion Healing, Apical Periodontitis","enrollment":60},{"nctId":"NCT04155567","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-123 After Intravenous Infusion in Japanese Healthy Adult Male Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2019-11-13","conditions":"Healthy Volunteers","enrollment":10},{"nctId":"NCT05761756","phase":"NA","title":"Oxygen Toxicity: Mechanisms in Humans","status":"RECRUITING","sponsor":"Duke University","startDate":"2023-11-28","conditions":"Oxygen Toxicity, Hypercapnia, Seizures","enrollment":62},{"nctId":"NCT03159390","phase":"NA","title":"Metabolism of Ornithine Phenylacetate","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2015-02-03","conditions":"Healthy","enrollment":20},{"nctId":"NCT05877027","phase":"NA","title":"Exercise vs. Topical Diclofenac vs. PRP","status":"COMPLETED","sponsor":"Istanbul University - Cerrahpasa","startDate":"2024-03-20","conditions":"Gonarthrosis","enrollment":82},{"nctId":"NCT06632015","phase":"NA","title":"Effect of DCS on Post-Endodontic Pain","status":"COMPLETED","sponsor":"Mustafa Kemal University","startDate":"2024-01-22","conditions":"Post Endodontic Pain","enrollment":90},{"nctId":"NCT07131527","phase":"NA","title":"Comparison Between Oral Gabapentin Versus Diclofenac Sodium in Post-operative Analgesia Laparoscopic Cholecystectomy","status":"RECRUITING","sponsor":"Sohag University","startDate":"2025-07-14","conditions":"Cholecystitis, Chronic","enrollment":60},{"nctId":"NCT05536011","phase":"","title":"WAKIX® (Pitolisant) Pregnancy Registry","status":"RECRUITING","sponsor":"Harmony Biosciences Management, Inc.","startDate":"2021-08-24","conditions":"Pregnancy Related, Narcolepsy","enrollment":1329},{"nctId":"NCT06937853","phase":"NA","title":"Effect of Genetic Polymorphisms on Response to Preoperative NSAIDs in Endodontic Postoperative Pain Management","status":"RECRUITING","sponsor":"Ataturk University","startDate":"2024-05-10","conditions":"Postoperative Pain","enrollment":200},{"nctId":"NCT06207253","phase":"PHASE2, PHASE3","title":"The Antimicrobial Potential of Diclofenac Sodium as an Intracanal Medicament","status":"RECRUITING","sponsor":"British University In Egypt","startDate":"2025-11","conditions":"Endodontic Disease, Pulp Disease, Dental, Intracanal Medication","enrollment":48},{"nctId":"NCT02406014","phase":"PHASE4","title":"Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-04","conditions":"Actinic Keratosis (AK)","enrollment":502},{"nctId":"NCT06829030","phase":"PHASE1, PHASE2","title":"Comparison of the Efficacy of Diclofenac Sodium and Subcutaneous 5% Dextrose Injection in Low Back Pain.","status":"ENROLLING_BY_INVITATION","sponsor":"Aksaray University Training and Research Hospital","startDate":"2024-07-15","conditions":"Low Back Pain, Mechanical","enrollment":150},{"nctId":"NCT05387525","phase":"PHASE4","title":"A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp","status":"ACTIVE_NOT_RECRUITING","sponsor":"Almirall, S.A.","startDate":"2022-10-24","conditions":"Keratosis, Actinic","enrollment":447},{"nctId":"NCT00597909","phase":"PHASE2","title":"Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy","status":"TERMINATED","sponsor":"Amgen","startDate":"2007-12","conditions":"Hepatic Encephalopathy","enrollment":1},{"nctId":"NCT00977600","phase":"PHASE1","title":"A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-03","conditions":"Healthy","enrollment":24},{"nctId":"NCT06342648","phase":"NA","title":"Intracutaneous Sterile Water and Diclofenac Sodium Injections in Renal Colic","status":"NOT_YET_RECRUITING","sponsor":"Suez Canal University","startDate":"2024-05-01","conditions":"Renal Colic","enrollment":570},{"nctId":"NCT06090500","phase":"NA","title":"Effect of Submucosal Cryotherapy on Postoperative Endodontic Pain","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-03-20","conditions":"Post-endodontic Pain","enrollment":52},{"nctId":"NCT05641246","phase":"PHASE2","title":"Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine","status":"COMPLETED","sponsor":"German University in Cairo","startDate":"2022-12-08","conditions":"Hand and Foot Syndrome","enrollment":86},{"nctId":"NCT06186921","phase":"NA","title":"Intraligamentary Injections and Post-endodontic Pain","status":"UNKNOWN","sponsor":"Jamia Millia Islamia","startDate":"2023-12-02","conditions":"Pulpitis","enrollment":140},{"nctId":"NCT06111573","phase":"PHASE4","title":"Comparative Evaluation of the Effectiveness of Diclofenac Sodium Versus Vitamin D on Myofascial Pain","status":"COMPLETED","sponsor":"Yuzuncu Yil University","startDate":"2022-06-01","conditions":"Myofascial Pain Dysfunction Syndrome,Temporomandibular Joint","enrollment":40},{"nctId":"NCT06105827","phase":"PHASE4","title":"Clinical Study of Ningmitai Capsule on Promoting the Passage of Residual Fragments After Ureteroscopic Lithotripsy","status":"COMPLETED","sponsor":"Xintian Pharmaceutical","startDate":"2016-10-02","conditions":"Ureteral Calculi","enrollment":251},{"nctId":"NCT04585334","phase":"PHASE4","title":"Effectiveness of Tricortin 1000 in Patients Affected by Chronic Low Back Pain","status":"UNKNOWN","sponsor":"Fidia Farmaceutici s.p.a.","startDate":"2019-03-25","conditions":"Low Back Pain, Mechanical","enrollment":300},{"nctId":"NCT04976088","phase":"PHASE3","title":"Clinical Trial With Diclofenac Sodium Medicated Plaster in Patients With Impact Injuries of the Limbs","status":"COMPLETED","sponsor":"Fidia Farmaceutici s.p.a.","startDate":"2018-05-25","conditions":"Trauma Injury, Inflammation","enrollment":214},{"nctId":"NCT05829707","phase":"PHASE4","title":"Long-term Outcomes of Breast Cancer Patients After Wound Infiltration Analgesia","status":"COMPLETED","sponsor":"Osijek University Hospital","startDate":"2009-01-05","conditions":"Postoperative Analgesia, Hand Strength, Health Related Quality of Life","enrollment":120},{"nctId":"NCT05626140","phase":"PHASE3","title":"COMPARISON OF EFFICACY OF DIFFERENT DRUG COMBINATIONS IN ACUTE SCIATICA","status":"COMPLETED","sponsor":"Pakistan Institute of Medical Sciences","startDate":"2021-09-28","conditions":"Sciatica Acute, Sciatica","enrollment":120},{"nctId":"NCT05582421","phase":"EARLY_PHASE1","title":"Effect of Diclofenac Sodium Versus Calcium Hydroxide as Intracanal Medication on the Intensity of Postoperative Pain, Bacterial Load Reduction and MMP-9 Levels in Patients With Necrotic Pulp.","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2022-12","conditions":"Necrotic Pulp, Apical Periodontitis","enrollment":30},{"nctId":"NCT04592016","phase":"NA","title":"Evaluate the Ability of dOFM for BE Testing of Topically Applied Diclofenac Sodium Products in Healthy Subjects","status":"COMPLETED","sponsor":"Joanneum Research Forschungsgesellschaft mbH","startDate":"2020-10-08","conditions":"Healthy","enrollment":22},{"nctId":"NCT05313997","phase":"","title":"The Incidence of Thoracic Disc Herniation in Patients Presenting With Chronic Upper Back Pain","status":"COMPLETED","sponsor":"Kocaeli University","startDate":"2022-05-24","conditions":"Thoracic Disc Herniation","enrollment":194},{"nctId":"NCT05488925","phase":"PHASE4","title":"Comparison of Preoperative Analgesics on the Efficacy of Inferior Alveolar Nerve Block.","status":"COMPLETED","sponsor":"Farjad Zafar","startDate":"2021-06-21","conditions":"Symptomatic Irreversible Pulpitis","enrollment":120},{"nctId":"NCT03529097","phase":"PHASE4","title":"Evaluation of the Roll of IV Fluids in the Treatment of Renal Colic","status":"WITHDRAWN","sponsor":"Sheba Medical Center","startDate":"2018-06-01","conditions":"Renal Colic","enrollment":""},{"nctId":"NCT04128462","phase":"PHASE3","title":"MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function","status":"WITHDRAWN","sponsor":"Mallinckrodt","startDate":"2021-11","conditions":"Hepatic Encephalopathy","enrollment":""},{"nctId":"NCT03846843","phase":"PHASE1","title":"OCR002-SP103 - Oral Immediate Release Study","status":"COMPLETED","sponsor":"Ocera Therapeutics, Inc.","startDate":"2016-08-15","conditions":"Cirrhosis","enrollment":30},{"nctId":"NCT01966419","phase":"PHASE2","title":"Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)","status":"COMPLETED","sponsor":"Ocera Therapeutics, Inc.","startDate":"2014-01-07","conditions":"Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy","enrollment":231},{"nctId":"NCT04432558","phase":"","title":"Postoperative Effects of Preoperative Anxiety","status":"COMPLETED","sponsor":"Baskent University","startDate":"2017-04-12","conditions":"Anxiety, Pain, Postoperative","enrollment":42},{"nctId":"NCT03712280","phase":"PHASE2","title":"MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2018-12-01","conditions":"Hepatic Cirrhosis, Hepatic Encephalopathy (HE)","enrollment":50},{"nctId":"NCT01634230","phase":"","title":"Emergency Use of OCR-002 in Acute Liver Failure (ALF)","status":"NO_LONGER_AVAILABLE","sponsor":"Ocera Therapeutics, Inc.","startDate":"","conditions":"Acute Liver Failure","enrollment":""},{"nctId":"NCT04860167","phase":"NA","title":"Sedation for Patients Undergoing Endoscopic Retrograde Cholangiopancreatography","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2018-09-10","conditions":"Biliary Colic","enrollment":90},{"nctId":"NCT00640432","phase":"PHASE4","title":"Safety And Efficacy Of Celecoxib Versus Sodium Diclofenac In The Treatment Of Acute Low Back Pain","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-10","conditions":"Low Back Pain","enrollment":244},{"nctId":"NCT04615702","phase":"","title":"Evidence Based Management of Acute Biliary Pancreatitis","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2017-05-15","conditions":"Acute Pancreatitis","enrollment":30},{"nctId":"NCT04591795","phase":"PHASE2","title":"Sahastara Remedy Extract Capsule in Primary Osteoarthritis of Clinical Trial Phase II","status":"UNKNOWN","sponsor":"Mr NARIN KAKATUM","startDate":"2018-01-01","conditions":"Osteoarthritis","enrollment":80},{"nctId":"NCT04585321","phase":"PHASE1","title":"Comparative Bioavailability and Local Tolerability of Two Topical Diclofenac Plasters Applied Once and Twice a Day","status":"COMPLETED","sponsor":"Fidia Farmaceutici s.p.a.","startDate":"2017-11-28","conditions":"Bioequivalence Study","enrollment":52},{"nctId":"NCT02985671","phase":"PHASE3","title":"To Evaluate the Superiority of Fixed Combination (Orfenadrine 35mg, Acetaminophen 325mg, Caffeine 65mg and Diclofenac Sodium 50mg) Compared to Voltaren® (Diclofenac Sodium 50mg) in the Treatment of Acute Postural Low Back Pain.","status":"UNKNOWN","sponsor":"Ache Laboratorios Farmaceuticos S.A.","startDate":"2021-01","conditions":"Postural Low Back Pain, Mechanical Low Back Pain","enrollment":110},{"nctId":"NCT04511195","phase":"PHASE2","title":"Effectiveness and Safety of Sphaeralcea Angustifolia Standardized Extract as a Topical Treatment of Knee Osteoarthritis","status":"UNKNOWN","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2020-07-10","conditions":"Knee Osteoarthritis","enrollment":100},{"nctId":"NCT01962987","phase":"PHASE3","title":"A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2013-03","conditions":"Actinic Keratosis","enrollment":476},{"nctId":"NCT03178539","phase":"PHASE2, PHASE3","title":"Comparative Study Between the Effect of Diclofanic and Ketorolac in Post Tonsillectomy Pain Management","status":"COMPLETED","sponsor":"Assiut University","startDate":"2017-01-31","conditions":"Pain, Acute","enrollment":100},{"nctId":"NCT04341402","phase":"PHASE2","title":"Systemic Uptake of Diclofenac Sodium in Combination With Miconazole as Antifungal Nail Gel When Applied Daily With Monitoring of Hepatic and Renal Enzymes, and Serum Levels of Diclofenac 12 Hours After Application, and at 3 and 6 Months Study","status":"UNKNOWN","sponsor":"William N Handelman","startDate":"2020-05-01","conditions":"Tinea Unguium, Onychomycosis","enrollment":30},{"nctId":"NCT04331210","phase":"NA","title":"Rectal Versus Oral Diclofenac Sodium in Relieving Post Episiotomy Pain","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-09-01","conditions":"Episiotomy Wound","enrollment":1024},{"nctId":"NCT03825016","phase":"PHASE2","title":"Lidocaine Infusion in Hystroscopy","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2017-08-01","conditions":"Pain","enrollment":44},{"nctId":"NCT01119898","phase":"PHASE2","title":"Exploratory Study of PENNSAID Gel to Treat Symptoms of Knee Osteoarthritis","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2010-08-02","conditions":"Osteoarthritis of the Knee","enrollment":260},{"nctId":"NCT02051452","phase":"PHASE1, PHASE2","title":"Reversal of General Anesthesia With Methylphenidate","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-11","conditions":"Post Operative Cognitive Dysfunction, Emergence From Anesthesia","enrollment":32},{"nctId":"NCT03714672","phase":"PHASE3","title":"Tramadol/Diclofenac Fixed-dose Combination Phase III Trial in Acute Pain After Third Molar Extraction","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2017-08-26","conditions":"Acute Pain","enrollment":1151},{"nctId":"NCT01412840","phase":"NA","title":"Sterile Water Injections for Relieving Ureterolithiasis Pain","status":"WITHDRAWN","sponsor":"University of Skövde","startDate":"2014-01","conditions":"Ureterolithiasis, Pain","enrollment":""},{"nctId":"NCT03074162","phase":"PHASE1","title":"Comparison of the Bioavailability of Diclofenac in a Combination Product (Diclofenac 2% + Capsaicin 0.075% Topical Gel) With Two Diclofenac Only Products, Diclofenac Mono Gel 2% and Voltarol® 12 Hour Emulgel 2.32% Gel, in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-04-20","conditions":"Healthy","enrollment":48},{"nctId":"NCT03831321","phase":"PHASE4","title":"The Effect of Preemptive Analgesia On The Comfort Of Patient and Doctor, in Cystoscopy","status":"UNKNOWN","sponsor":"Taha Uçar","startDate":"2018-12-11","conditions":"Bladder Cancer, Benign Prostate Hyperplasia, Hematuria","enrollment":144},{"nctId":"NCT03826550","phase":"PHASE3","title":"Therapeutic Equivalence of Diclofenac Sodium Gel 3% vs Solaraze ® in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Encube Ethicals Pvt. Ltd.","startDate":"2018-01-12","conditions":"Actinic Keratoses","enrollment":655},{"nctId":"NCT03766984","phase":"PHASE1","title":"Pharmacokinetic Non-interaction Study With a Fixed-dose Combination Tablet With Tramadol and Diclofenac","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2015-06-07","conditions":"Pharmacokinetics","enrollment":36},{"nctId":"NCT01548690","phase":"PHASE2","title":"Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury","status":"COMPLETED","sponsor":"William Lee","startDate":"2012-06","conditions":"Acute Liver Failure, Acute Liver Injury","enrollment":47},{"nctId":"NCT02598102","phase":"PHASE2","title":"Efficacy of Preprocedural Diclofenac in Males Undergoing Double J Stent Removal Under Local Anesthesia","status":"COMPLETED","sponsor":"Institute of Nephro Urology, Bangalore","startDate":"2015-04","conditions":"Pain","enrollment":150},{"nctId":"NCT02876432","phase":"NA","title":"Evaluating Acupuncture Relationship With the Catecholaminergic Pathway","status":"COMPLETED","sponsor":"Universidad Autónoma Benito Juárez de Oaxaca","startDate":"2016-10","conditions":"Low Back Pain","enrollment":30},{"nctId":"NCT03520595","phase":"NA","title":"Analgesic Efficacy of Arnica Montana in Comparison With Diclofenac Sodium Following a Periodontal Surgical Procedure","status":"COMPLETED","sponsor":"Tatyasaheb Kore Dental College","startDate":"2016-12-01","conditions":"Crown Lengthening Procedure With Ostectomy","enrollment":60},{"nctId":"NCT03472339","phase":"PHASE4","title":"Clinical Trial Comparing Intravenous and Oral Diclofenac and Pharmacokinetics","status":"UNKNOWN","sponsor":"Hamad Medical Corporation","startDate":"2018-01-15","conditions":"Pain Management, Limb Injury","enrollment":300},{"nctId":"NCT03458923","phase":"PHASE4","title":"Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema.","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2015-01","conditions":"Diabetic Macular Edema","enrollment":30},{"nctId":"NCT03449940","phase":"NA","title":"Penile Fracture: A Comparison of Erectile Function After Immediate Repair Versus Delayed Repair","status":"COMPLETED","sponsor":"Ministry of Health, Jamaica","startDate":"2015-01","conditions":"Erectile Dysfunction","enrollment":46},{"nctId":"NCT02403687","phase":"","title":"Prospective Analgesic Compound Efficacy (PACE) Study","status":"COMPLETED","sponsor":"Express Specialty Pharmacy","startDate":"2015-06","conditions":"Arthritis, Tendonitis, Gout","enrollment":300},{"nctId":"NCT02100670","phase":"PHASE3","title":"A Multicenter Efficacy Study of a Diclofenac+Menthol Gel in Subjects With Ankle Sprain","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-11-01","conditions":"Pain","enrollment":385},{"nctId":"NCT03221946","phase":"PHASE4","title":"A Comparative Evaluation of Diclofenac Sodium Transdermal Patch, Oral Diclofenac Sodium With Intramuscular Injections of Diclofenac Sodium in Patients Suffering From Oral Pain","status":"COMPLETED","sponsor":"Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre","startDate":"2016-01-31","conditions":"Orofacial Pain","enrollment":90},{"nctId":"NCT01190722","phase":"PHASE4","title":"A Study Comparing Etoricoxib and Diclofenac Sodium in Post Hallux Valgus Surgery Pain","status":"WITHDRAWN","sponsor":"Karolinska Institutet","startDate":"2010-11-10","conditions":"Hallux Valgus, Postoperative Pain","enrollment":""},{"nctId":"NCT03090971","phase":"PHASE2","title":"Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1","status":"COMPLETED","sponsor":"Fundação Educacional Serra dos Órgãos","startDate":"2017-02-15","conditions":"Neurofibromatosis 1, Cutaneous Neurofibroma","enrollment":7},{"nctId":"NCT02714231","phase":"PHASE4","title":"Oral Diclofenac Sodium Versus Oral Hyoscine Butyl Bromide During Intrauterine Device Insertion","status":"COMPLETED","sponsor":"Assiut University","startDate":"2016-03","conditions":"Family Planning","enrollment":100},{"nctId":"NCT02169154","phase":"PHASE1","title":"A Safety Study to Investigate the Skin Irritancy Potential of Diclofenac-Menthol Gel","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-06-01","conditions":"Pain","enrollment":36},{"nctId":"NCT02201238","phase":"PHASE1","title":"Pharmacokinetics Study Comparing Topical Diclofenac/Menthol Gels With Voltaren Gel and Oral Diclofenac Sodium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-01","conditions":"Pain","enrollment":18},{"nctId":"NCT02611804","phase":"PHASE3","title":"A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2015-10","conditions":"Actinic Keratosis","enrollment":492},{"nctId":"NCT00476593","phase":"NA","title":"Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2005-09","conditions":"Uveitis, Iritis, Iridocyclitis","enrollment":218},{"nctId":"NCT00914160","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability of Diclofenac Sodium 50 mg Enteric-Coated Tablets Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"1993-08","conditions":"Inflammation","enrollment":18},{"nctId":"NCT00913224","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability of Diclofenac Sodium 50 mg Enteric-Coated Tablets","status":"COMPLETED","sponsor":"Sandoz","startDate":"1993-04","conditions":"Inflammation","enrollment":38},{"nctId":"NCT00913887","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability of Diclofenac Sodium 75 mg Enteric-Coated Tablets Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"1994-04","conditions":"Inflammation","enrollment":18},{"nctId":"NCT02445599","phase":"PHASE4","title":"Diclofenac Premedication, as the Effect of Preemptive Analgesia After Post-thoracotomy Chest and Shoulder Pain","status":"COMPLETED","sponsor":"University of Debrecen","startDate":"2014-04","conditions":"Pain, Inadequate or Impaired Respiratory Function","enrollment":3},{"nctId":"NCT03041779","phase":"PHASE2","title":"Comparison Between Rectal Suppository Acetaminophen and Diclofenac Sodium as Analgesia for Postpartum Perineal Tear","status":"COMPLETED","sponsor":"Clinical Research Centre, Malaysia","startDate":"2015-10","conditions":"Perineal Tear, Perineal Laceration (Obstetric)","enrollment":909},{"nctId":"NCT02837770","phase":"NA","title":"Effect of Topical and Oral Diclofenac on Pain Related to Intravitreal Injections","status":"COMPLETED","sponsor":"University Hospital of Patras","startDate":"2016-07","conditions":"Pain","enrollment":76},{"nctId":"NCT02652312","phase":"NA","title":"Dexmedetomidine and Desflurane Consumption","status":"COMPLETED","sponsor":"Theodor Bilharz Research Institute","startDate":"2016-02","conditions":"Anesthesia","enrollment":40},{"nctId":"NCT02339428","phase":"PHASE3","title":"Diclophenac Versus Placebo for Pain Control in Diagnostic Colonoscopy","status":"COMPLETED","sponsor":"University Hospital Rijeka","startDate":"2015-01","conditions":"Anemia","enrollment":90},{"nctId":"NCT02918812","phase":"PHASE4","title":"Intracervical Lidocaine Versus Intramuscular Diclofenac for Pain Relief in HSG in a Tertiary Hospital in Kano","status":"UNKNOWN","sponsor":"Bayero University Kano, Nigeria","startDate":"2016-09","conditions":"Female Infertility of Tubal Origin","enrollment":140},{"nctId":"NCT02714842","phase":"PHASE1","title":"Delayed Release Diclofenac Sodium Formulation vs Voltaren®","status":"COMPLETED","sponsor":"BDD Pharma Ltd","startDate":"2016-03","conditions":"Pain","enrollment":36},{"nctId":"NCT02752971","phase":"PHASE3","title":"Wound Infiltration With Sodium Diclofenac vs Bupivacaine for Postoperative Pain Following Appendectomy","status":"COMPLETED","sponsor":"Hospital Central Dr. Luis Ortega","startDate":"2015-02","conditions":"Postoperative Pain","enrollment":43},{"nctId":"NCT00523120","phase":"PHASE2","title":"Topical Voltaren in Otitis Externa","status":"TERMINATED","sponsor":"Sieff Medical Center","startDate":"2008-09","conditions":"Otitis Externa","enrollment":20},{"nctId":"NCT02495831","phase":"PHASE1","title":"Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy Volunteers","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2015-05","conditions":"Healthy","enrollment":24},{"nctId":"NCT02698306","phase":"NA","title":"Comparison of the Use of Dexamethasone and Diclofenac Sodium in Immediate Post-Operative Care in Third Molar Surgery","status":"UNKNOWN","sponsor":"Hospital Geral de Vila Penteado","startDate":"2015-02","conditions":"Impacted Third Molar Tooth","enrollment":30},{"nctId":"NCT02658721","phase":"PHASE3","title":"Effects of Systemic or Adjunct Tramadol Addition to Lidocaine Used for IVRA in Patients Undergoing Hand Surgery","status":"COMPLETED","sponsor":"Bagcilar Training and Research Hospital","startDate":"2013-01","conditions":"Anesthesia","enrollment":60},{"nctId":"NCT01306318","phase":"NA","title":"A Clinical Study in Healthy Male Volunteers to Compare the Bioequivalence of Fixed Dose Combination of Eperisone Hydrochloride 50mg Plus Diclofenac Sodium 50mg as Capsule With Eperisone Hydrochloride 50mg and Diclofenac Sodium 50mg Tablets Under Fasting Conditions (Study 013-10)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2011-02","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT01434108","phase":"PHASE2, PHASE3","title":"Effects of the Administration of Ornithine Phenylacetate in Patients With Cirrhosis and Upper Gastrointestinal Bleeding","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2011-10","conditions":"Gastrointestinal Bleeding, Cirrhosis","enrollment":48},{"nctId":"NCT02087748","phase":"PHASE4","title":"An Investigator Initiated, Within-Subject, Proof of Concept Study to Assess the Efficacy and Safety of Voltaren Gel in Subjects With DOMS","status":"COMPLETED","sponsor":"Lotus Clinical Research, LLC","startDate":"2014-03","conditions":"Pain, Delayed Onset Muscle Soreness","enrollment":24},{"nctId":"NCT02253446","phase":"PHASE4","title":"A Comparison of Analgesic İmpacts of Piroxicam and Diclofenac Sodium in the Treatment of Primary Dysmenorrhea","status":"COMPLETED","sponsor":"Pamukkale University","startDate":"2013-05","conditions":"Primary Dysmenorrhea","enrollment":400},{"nctId":"NCT01706588","phase":"PHASE2","title":"Injectable Diclofenac for the Prevention of Post-operative Dental Pain","status":"COMPLETED","sponsor":"IBSA Institut Biochimique SA","startDate":"2013-01","conditions":"Pain","enrollment":75},{"nctId":"NCT01511939","phase":"PHASE3","title":"Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants","status":"COMPLETED","sponsor":"Nathan Wei, MD, FACP, FACR:","startDate":"2012-02","conditions":"Osteoarthritis of the Knee, Coagulopathy","enrollment":22}],"_emaApprovals":[],"_faersSignals":[{"count":16,"reaction":"DRUG INEFFECTIVE"},{"count":5,"reaction":"DRUG INEFFECTIVE FOR UNAPPROVED INDICATION"},{"count":4,"reaction":"OFF LABEL USE"},{"count":3,"reaction":"AMMONIA INCREASED"},{"count":3,"reaction":"HYPERAMMONAEMIA"},{"count":3,"reaction":"HYPERAMMONAEMIC ENCEPHALOPATHY"},{"count":3,"reaction":"MYELOSUPPRESSION"},{"count":3,"reaction":"RESPIRATORY ALKALOSIS"},{"count":3,"reaction":"STATUS EPILEPTICUS"},{"count":2,"reaction":"CONDITION AGGRAVATED"}],"administration":{"route":"Intravenous"},"crossReferences":{"chemblId":"CHEMBL1200358"},"_approvalHistory":[],"publicationCount":123,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"approved","brandName":"SODIUM PHENYLACETATE","genericName":"SODIUM PHENYLACETATE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1987","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T03:59:06.508473+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}